Clinical trials
6 active studies led by Ocugen, of 12 in all
Source: ClinicalTrials.gov, Studies with Ocugen (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 2Markets in public records
- 0Regions & countries
- 6Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Ocugen or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Ocugen
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Website
- ocugen.com
- Stock listing
- NASDAQ: OCGN
- Type
- Medicines
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1372299.
Trials over time
Studies Ocugen leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Ocugen or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Ocugen: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Ocugen is in.
From our blog
Stories on the topics Ocugen works in.
Bone and Joint Health: Supplements for an Ageing Population
1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…
Read
Eye Health Supplements: Screens, Ageing and Vision
2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…
Read
Collagen Supplements: Skin, Joints and Real Evidence
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read